Autoimmune Heparin-Induced Thrombocytopenia
Journal of Clinical Medicine · 03.11.2023 · 12 (21) · 6921
DOI: 10.3390/jcm12216921 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.11.2023. Verfasst von Theodore E Warkentin. Beteiligte Einrichtung: Department of Pathology and Molecular Medicine and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON …. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 225 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Autoimmune thrombocytopenia (aHIT) is a severe subtype of heparin-induced thrombocytopenia (HIT) with atypical clinical features caused by highly pathological IgG antibodies (“aHIT antibodies”) that activate platelets even in the absence of heparin. The clinical features of aHIT include: the onset or worsening of thrombocytopenia despite stopping heparin (“delayed-onset HIT”), thrombocytopenia persistence despite stopping heparin (“persisting” or “refractory HIT”), or triggered by small amounts of heparin (heparin “flush” HIT), most cases of fondaparinux-induced HIT, and patients with unusually severe HIT (e.g., multi-site or microvascular thrombosis, overt disseminated intravascular coagulation [DIC]). Special treatment approaches are required. For example, unlike classic HIT, heparin cessation does not result in de-escalation of antibody-induced hemostasis activation, and thus high-dose intravenous immunoglobulin (IVIG) may be indicated to interrupt aHIT-induced platelet activation; therapeutic plasma exchange may be required if high-dose IVIG is ineffective. Also, aHIT patients are at risk for treatment failure with (activated partial thromboplastin time [APTT]-adjusted) direct thrombin inhibitor (DTI) therapy (argatroban, bivalirudin), either because of APTT confounding (where aHIT-associated DIC and resulting APTT prolongation lead to systematic underdosing/interruption of DTI therapy) or because DTI inhibits thrombin-induced protein C activation. Most HIT laboratories do not test for aHIT antibodies, contributing to aHIT under-recognition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Molecular Medicine and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8N 3Z5, Canada.
- Service of Benign Hematology, Hamilton Health Sciences (General Site), Hamilton, ON L8L 2X2, Canada.
- Transfusion Medicine, Hamilton Regional Laboratory Medicine Program, Hamilton, ON L8L 2X2, Canada.
ORCID-Profile: Theodore E Warkentin
Zitieren
APA
Warkentin, T. E. (2023). Autoimmune Heparin-Induced Thrombocytopenia. Journal of Clinical Medicine, 12(21), 6921. https://doi.org/10.3390/jcm12216921
Vancouver
Warkentin TE. Autoimmune Heparin-Induced Thrombocytopenia. Journal of Clinical Medicine. 2023;12(21):6921. doi:10.3390/jcm12216921
BibTeX
@article{Warkentin2023,
author = {Warkentin, Theodore E},
title = {Autoimmune Heparin-Induced Thrombocytopenia},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {21},
pages = {6921},
doi = {10.3390/jcm12216921}
}
EUVIMED